The quest for accurate target validation
Posted: 9 April 2015 | Sheraz Gul (Fraunhofer-IME SP)
Preview of the upcoming foreword in our April issue, written by Sheraz Gul, Vice President and Head of Biology at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany…
The identification and implication of proteins in disease processes is ever increasing as evidenced by the number of peer-reviewed publications citing such links. This is not surprising given the increase in the number of organisations involved in drug discovery outside the pharmaceutical and biotech industry. However, it is often the case that a target is implicated in different diseases with varying levels of confidence depending on the nature of work reported. As a consequence, robust target validation relating to disease association is often lacking and it is not uncommon that further research negates the original hypothesis. Although this offers the opportunity to discover first-in-class drugs, progressing small molecule drug discovery for such targets is often extremely challenging.
The rest of this article is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!